These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
FCP Paper_Final.pdf (279.39 kB)

Performance of a FRET-Based Point-of-Care Immunoassay for the Quantitation of Fecal Calprotectin

submitted on 16.02.2021, 22:35 and posted on 18.02.2021, 04:35 by Manisha Yadav, Michael Skinner, Rukmini Reddy, Matthew Wong, Kevin Chon, Raj Srikrishnan, Ruo Huang, Edgar Ong, Kurt Bray, Valerie Day, Larry Mimms, Michael Hale

A fast (~5 min), time-resolved fluorescence resonance energy transfer based immunoassay (Procise FCP) was developed for the point-of-care quantitative detection of fecal calprotectin (FCP) using 15 mg of fecal specimen eluted in collection fluid from the Procise Stool Collection Device™. Studies were performed to characterize analytical performance of the Procise FCP assay on the ProciseDx™ analyzer.

The Procise FCP assay showed good analytical performance with respect to sensitivity, specificity, linearity, and precision suitable for routine clinical use in a point-of-care setting as well as excellent analytical agreement with a current commercial FCP measurement method.

Results indicate that the Procise FCP assay is sensitive, specific, and precise yielding results in less than 5 minutes. This indicates the Procise FCP assay is useful for obtaining fast and accurate FCP quantitation, thus avoiding delays inherent to current methods and enabling immediate clinical assessment to be made during a single patient visit.


Email Address of Submitting Author


ProciseDx Inc.


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

All authors are employees of ProciseDx Inc.